title: Six week safety study of 2% MK-927 administered twice daily to ocular hypertensive volunteers.
abstract: Ocular hypertensive patients were enrolled in a 6-week double-masked safety study of 2% MK-927 (27 patients), a topically active carbonic anhydrase inhibitor, administered bilaterally b.i.d.; 9 additional patients received 0.5% timolol as the control agent. Intraocular pressure (IOP) was measured weekly prior to a.m. drug administration; twelve hour diurnal curves were performed prestudy and at 3 and 6 weeks. The mean reduction of IOP prior to a.m. drug administration ranged from 1.2 +/- 4.4 mm Hg (SD) to 3.0 +/- 4.2 mm Hg with MK-927 and from 4.7 +/- 3.9 mm Hg to 8.8 +/- 0.6 mm Hg with timolol. Mean outflow facility measured tonographically prestudy and on days 33 to 42 four hours after a.m. drug administration was unchanged in both groups. Corneal sensitivity (Cochet-Bonnet), corneal thickness (ultrasound pachymetry), Schirmer tear testing, and extensive ophthalmologic and medical examinations, and hematologic studies were not substantially altered throughout the study. In this longest chronic administration study to date, MK-927 did not cause adverse ocular or systemic side effects.
authors.affiliation: Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York.
authors.forename: J B
authors.initials: JB
authors.lastname: Serle
authors.forename: J
authors.initials: J
authors.lastname: Lustgarten
authors.forename: E A
authors.initials: EA
authors.lastname: Lippa
authors.forename: C B
authors.initials: CB
authors.lastname: Camras
authors.forename: L
authors.initials: L
authors.lastname: Framm
authors.forename: J E
authors.initials: JE
authors.lastname: Payne
authors.forename: D
authors.initials: D
authors.lastname: Deasy
authors.forename: S M
authors.initials: SM
authors.lastname: Podos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D012449:Safety; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; D013999:Timolol; C057921:sezolamide